This study found serological evidence for bat-borne coronavirus transmission to people. Direct contact with bats was not identified as a risk factor. However, self-reported severe acute respiratory infection (SARI) and/or influenza-like illness (ILI) was linked to human interaction with other wildlife and livestock, suggesting that there may be other zoonotic exposures leading to clinical illness in these populations.
The low levels of sero-positivity found in the study could reflect a number of factors: 1) the rarity of spillover and bat-to-human transmission, as has been reported for other virus-host systems [[50], [51], [52], [53], [54]]; 2) the use of a snowball technique for sample selection that could have biased the population sampled; 3) the limited diversity of CoVs that this study tested for; 4) the possibility that these infections cause high mortality rates and therefore the number of survivors and number of seropositive people is low, although this seems unlikely because the mortality rate from SARS was >10% during an outbreak that included hospital exposure and therefore likely high infectious doses [55,56]; and 5) that antibodies to these viruses wane rapidly in humans. The latter hypothesis is supported by findings that antibodies to SARS decline rapidly (2–3 years) after illness [57]. Expanding this approach to a larger population, using a longitudinal (repeated sampling) approach, and targeting people who are in the higher-risk categories identified here may provide a larger number of sero-positives and more critical information on the driving factors of viral spillover. However, despite the small sample sizes, this study suggests that there are a substantial number of people in rural Southern China who are exposed to bat-borne viruses, and that exposure likely occurs through the daily or normal practices of rural communities, rather than specific high-risk behaviours (e.g. wild animal hunting). Considering the proven potential of some SARSr-CoVs currently circulating in bats in southern China, to infect human cells, cause clinical signs in humanized mouse models, and lead to infections that cannot be treated with monoclonal therapies effective against SARS-CoV [[58], [59], [60]], this represents a clear and present danger to our biosafety and public health. Further studies to determine the relationship between SARSr-CoV and HKU10-CoV exposure and illness in people may help elucidate this risk and provide critical mitigation strategies.